Difference between revisions of "Pixantrone (Pixuvri)"
Jump to navigation
Jump to search
m |
m |
||
| Line 7: | Line 7: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *2012-05-10: Initial authorization as Pixuvri |
| − | *Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy. | + | *Uncertain date: Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy. |
==Also known as== | ==Also known as== | ||
*'''Code name:''' BBR 2778 | *'''Code name:''' BBR 2778 | ||
Revision as of 13:29, 9 May 2023
Mechanism of action
From the NCI Drug Dictionary: The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity. Route: IV
Diseases for which it is used
History of changes in EMA indication
- 2012-05-10: Initial authorization as Pixuvri
- Uncertain date: Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.
Also known as
- Code name: BBR 2778
- Generic name: pixantrone dimaleate
- Brand name: Pixuvri